NCT04367051 - Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

December 10, 2021

Study Completion Date

June 30, 2022

Conditions

Heart Failure

Interventions

DRUG

Withdrawal of Spironolactone

Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.

DRUG

Continuation of spironolactone

Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.

Trial Locations (1)

138-736

Asan Medical Center, Seoul